Warning: mkdir(): Permission denied in /data/Websites/newwiki-mpm/fuel/core/classes/log.php on line 122

Warning!

ErrorException [ Warning ]: mkdir(): Permission denied

COREPATH/classes/log.php @ line 122:

121:	
122:	mkdir($filepath, \Config::get('file.chmod.folders', 0777), true);
123:	umask($old);
ALK - Wiki-MPM

Search Results for: ALK

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel BIRC6 baculoviral IAP repeat containing 6
Novel CLNS1A chloride nucleotide-sensitive channel 1A
  • snRNP Assembly
Novel DLG2 discs large MAGUK scaffold protein 2
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
Novel DNMT3A DNA methyltransferase 3 alpha
  • PRC2 methylates histones and DNA
  • RMTs methylate histone arginines
  • SUMOylation of DNA methylation proteins
  • DNA methylation
  • Procaine
  • Decitabine
Novel HADHB hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta
  • Acyl chain remodeling of CL
  • Beta oxidation of myristoyl-CoA to lauroyl-CoA
  • mitochondrial fatty acid beta-oxidation of unsaturated fatty acids
  • Beta oxidation of palmitoyl-CoA to myristoyl-CoA
  • Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
  • Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
  • Beta oxidation of octanoyl-CoA to hexanoyl-CoA
  • Beta oxidation of hexanoyl-CoA to butanoyl-CoA
Novel HMGB1 high mobility group box 1
  • Apoptosis induced DNA fragmentation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TLR by endogenous ligand
  • Neutrophil degranulation
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • TRAF6 mediated NF-kB activation
  • Chloroquine
  • Ethyl pyruvate
Novel MSH2 mutS homolog 2
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Defective Mismatch Repair Associated With MSH3
  • Defective Mismatch Repair Associated With MSH2
  • Defective Mismatch Repair Associated With MSH6
  • TP53 Regulates Transcription of DNA Repair Genes
  • Colorectal cancer
  • Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
  • Ovarian cancer
Novel NLRC4 NLR family CARD domain containing 4
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • The IPAF inflammasome
  • The IPAF inflammasome
Novel RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
Novel SMC1A structural maintenance of chromosomes 1A
  • Meiotic synapsis
  • Separation of Sister Chromatids
  • Establishment of Sister Chromatid Cohesion
  • Cohesin Loading onto Chromatin
  • Resolution of Sister Chromatid Cohesion
  • SUMOylation of DNA damage response and repair proteins
  • Estrogen-dependent gene expression
  • Cornelia de Lange syndrome (CdLS)
Novel TSPAN16 tetraspanin 16
Novel TTC19 tetratricopeptide repeat domain 19
  • Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
DUSP19 dual specificity phosphatase 19
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
IKBKG inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • SUMOylation of immune response proteins
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • AGRO100
  • Tarenflurbil
  • Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
  • Incontinentia pigmenti
  • Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
IRS1 insulin receptor substrate 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Activated NTRK3 signals through PI3K
  • Growth hormone receptor signaling
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
JAK3 Janus kinase 3
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Interleukin receptor SHC signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • R-348
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Zanubrutinib
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
MDK midkine
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
NPM1 nucleophosmin 1
  • Nuclear import of Rev protein
  • Nuclear import of Rev protein
  • SUMOylation of transcription cofactors
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
  • Artenimol
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Isoprenaline
  • SF1126
  • Enzastaurin
  • Wortmannin

Page 1 out of 2 pages